ECSP077240A - Variantes mejoradas de la aprotinina - Google Patents

Variantes mejoradas de la aprotinina

Info

Publication number
ECSP077240A
ECSP077240A EC2007007240A ECSP077240A ECSP077240A EC SP077240 A ECSP077240 A EC SP077240A EC 2007007240 A EC2007007240 A EC 2007007240A EC SP077240 A ECSP077240 A EC SP077240A EC SP077240 A ECSP077240 A EC SP077240A
Authority
EC
Ecuador
Prior art keywords
improved
proteins
aprotinin variants
field
serine protease
Prior art date
Application number
EC2007007240A
Other languages
English (en)
Inventor
Kevin J Lumb
Stanley Horton
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of ECSP077240A publication Critical patent/ECSP077240A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se encuadra dentro del campo de proteínas que inhiben la actividad de la serina proteasa. La invención se relaciona asimismo con el campo de construcciones de ácidos nucleicos, vectores y células hospedadoras para la producción de proteínas inhibidoras de la serina proteasa, composiciones farmacéuticas que contienen dichas proteínas y métodos para su uso.
EC2007007240A 2004-07-13 2007-02-12 Variantes mejoradas de la aprotinina ECSP077240A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58765504P 2004-07-13 2004-07-13

Publications (1)

Publication Number Publication Date
ECSP077240A true ECSP077240A (es) 2007-03-29

Family

ID=35839810

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007240A ECSP077240A (es) 2004-07-13 2007-02-12 Variantes mejoradas de la aprotinina

Country Status (15)

Country Link
US (1) US20090005297A1 (es)
EP (1) EP1771464A4 (es)
JP (1) JP2008506391A (es)
KR (1) KR20070041749A (es)
CN (1) CN101014611A (es)
AU (1) AU2005271708A1 (es)
BR (1) BRPI0513267A (es)
CA (1) CA2573368A1 (es)
EC (1) ECSP077240A (es)
IL (1) IL180370A0 (es)
MA (1) MA28779B1 (es)
MX (1) MX2007000473A (es)
NO (1) NO20070640L (es)
RU (1) RU2007105137A (es)
WO (1) WO2006017355A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008110301A1 (de) * 2007-03-13 2008-09-18 Bayer Schering Pharma Aktiengesellschaft Aprotinin-varianten mit verbesserten eigenschaften
WO2009030464A2 (de) * 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
CN101412995B (zh) * 2007-10-17 2011-04-06 江苏正大天晴药业股份有限公司 聚乙二醇修饰的抑肽酶及其制备方法
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
WO2010088547A1 (en) * 2009-01-29 2010-08-05 Bayer Healthcare Llc Assays for detecting pegylated blood coagulation factors
DE102011013326A1 (de) 2011-03-08 2012-09-13 Solution Shop Ag Neue Fibrinolyse-Inhibitoren und deren mdizinische Verwendung
HUE049945T2 (hu) * 2012-03-03 2020-11-30 Immungene Inc Módosított antitest-interferon mutáns fúziós molekulák
US9605057B1 (en) * 2013-06-17 2017-03-28 Board Of Regents Of The University Of Texas System Endotrophin neutralization and use thereof
WO2017098516A1 (en) * 2015-12-10 2017-06-15 The National Institute for Biotechnology in the Negev Ltd. VARIANTS OF AMYLOID beta-PROTEIN PRECURSOR INHIBITOR DOMAIN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0573603T3 (da) * 1991-03-01 2003-10-20 Dyax Corp Inhibitorer af human neutrofil elastase og human cathepsin G
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CN101014611A (zh) 2007-08-08
WO2006017355A3 (en) 2006-12-14
EP1771464A2 (en) 2007-04-11
RU2007105137A (ru) 2008-08-20
US20090005297A1 (en) 2009-01-01
JP2008506391A (ja) 2008-03-06
NO20070640L (no) 2007-04-11
MA28779B1 (fr) 2007-08-01
AU2005271708A1 (en) 2006-02-16
CA2573368A1 (en) 2006-02-16
MX2007000473A (es) 2007-03-29
IL180370A0 (en) 2007-06-03
KR20070041749A (ko) 2007-04-19
BRPI0513267A (pt) 2008-05-06
WO2006017355A2 (en) 2006-02-16
EP1771464A4 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
ECSP077240A (es) Variantes mejoradas de la aprotinina
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
GEP20104974B (en) Carbonylamino pyrrolopyrazoles, protent kinase inhibitors
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
ECSP088262A (es) Proteínas de fusión de albúmina
EA200601562A1 (ru) Сокристаллы госсипола и их применение
ECSP10010735A (es) Compuestos químicos 251
EA201070247A1 (ru) Ингибиторы протеасом
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
SV2006002513A (es) Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
EA200870619A1 (ru) Модифицированный фермент дикамба-монооксигеназа и способы его применения
BR112012019042A2 (pt) "inibidores de serina protease tipo tripsina, e sua preparação e uso".
IN2012DN00801A (es)
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
AR051489A1 (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que los codifican